Navigation Links
ZeptoMetrix™ to Release Additional CE/IVD Marked Molecular Diagnostic Quality Controls
Date:7/31/2018

ZeptoMetrix™ Corporation (ZMC) announced today the release of 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory.

“We are pleased today to introduce two Group B Streptococcal molecular quality controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully support and provide our diagnostics industry with as many precise and dependable, non-infectious tools as we can to assist with accurate and reliable QC”, explains Shawn Smith, President and CEO of ZeptoMetrix.

Dedicated to strengthening its CE/IVD core, ZeptoMetrix has utilized its patented NATtrol™ inactivation treatment to provide following GBS CE/IVD molecular quality controls:

NATtrol GBS Positive Control (Product Number MDZ053)
NATtrol GBS Negative Control (Product Number MDZ054)

Together, the routine and repetitive use of NATtrol™ External Run Controls and Range Verification Panels enables laboratories to verify test performance, track and monitor daily test variation, lot-to-lot test kit performance and individual operator performance to provide assistance identifying trends in laboratory results.

Additional, ZeptoMetrix CE/IVD and IVD products include:

About ZeptoMetrix™
ZeptoMetrix Corporation (ZMC) is a renowned industry leader and innovator identified with quality, reliable and trusted products and services for infectious disease diagnostic development. ZeptoMetrix is a fully integrated biotechnology company whose offerings support all phases of research & development, validation, manufacturing and commercialization of diagnostic testing.

Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.

About NATtrol™
Globally, millions of people are tested for infectious diseases annually. The implications of reporting either a false positive or a false negative can be devastating to the patient. Accurate and sensitive diagnostics are necessary to confirm that laboratories are providing patients with proper testing results.

Utilizing ZeptoMetrix NATtrol External Run Controls on a consistent basis helps to monitor testing performance to maximize additional confidence in a patient’s reported results.

ZeptoMetrix NATtrol Molecular Diagnostic Products are an essential part of today’s fast growing market and are designed provide the safest, most accurate and cost effective support for critical microorganism detection.

The ZeptoMetrix NATtrol treatment blocks surface protein receptors on highly purified microorganisms rendering them non-infectious while allowing the internal nucleic acids to remain intact for molecular detection. Mimicking a true, infected clinical specimen, these ready-to-use non-infectious products are safe to use and refrigerator stable while controlling for all steps in molecular testing including: centrifugation, extraction, amplification and nucleic acid detection.

For Sales and/or information regarding ZeptoMetrix, ZeptoMetrix Molecular Quality Controls & Panels, and Development/Custom Services, please contact ZeptoMetrix Customer Relations directly.

Contact:
ZeptoMetrix Corporation, Customer Relations
878 Main Street
Buffalo, NY 14202
716-882-0920
custserv@zeptometrix.com
http://www.zeptometrix.com

Media:
Michael Hershfield, Vice President, Sales & Marketing                            
508-553-5852
mhershfield@zeptometrix.com

Read the full story at https://www.prweb.com/releases/zeptometrix_to_release_additional_ce_ivd_marked_molecular_diagnostic_quality_controls/prweb15658878.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. ZeptoMetrix™ (ZMC) to Release NATtrol™ Inactivated Zika Virus for the Development of Molecular Diagnostic Assays and Ongoing Clinical Laboratory Quality Control
2. ZeptoMetrix™ Corporation (ZMC) Announces the Release of Additional Zika Virus Culture Fluids
3. ZeptoMetrix™ and FIND Announce New Culture Panels to Develop High Sensitivity Malaria Test
4. EAG Announces New General Manager of Release-To-Production (RTP) Division
5. Smith & Nephew releases new Modular Rail System in collaboration with Dr. Dror Paley
6. HCCS Releases New Social Media Online Training Course
7. SoundMindz TM Releases ‘Anti-Anxiety TM’ Mobile App - A Complete Stress Therapy Program
8. BioPharm Insight Releases its Catalyst Monitor for April 2013
9. Why Plastic Water Baths Prevent the Contamination of Samples - Revolutionary Science Releases a Brand New Poly ProBath Video
10. Boca Bearings Releases Packaging Industry Bearings
11. Manipulating the Brain to Eliminate Fear or Restore Memories – Rudy Mazzocchi Releases the 2nd Novel in The EQUITY Series entitled "EQUITY of FEAR"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2019)... ... January 15, 2019 , ... With the U.S. Congress designating January as Cervical ... (STD) testing service, today announces tips to help reduce the risk of Cervical Cancer. , ... (HPV). Genital HPV is the #1 most common STD and an STI that ...
(Date:1/10/2019)... ... January 08, 2019 , ... ... innovative spinal implant company, announced today that SAGICO will be represented at ... The annual J.P. Morgan Healthcare Conference is the largest and most informative ...
(Date:1/7/2019)... , ... January 07, 2019 , ... ... clinical trials of its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 is ... Disease. The trial took place in South Korea. , This Phase 1 ...
(Date:1/4/2019)... ... 2019 , ... Calidi Biotherapeutics, Inc., a clinical-stage ... the founding of a scientific and medical advisory board (SMAB). The SMAB will ... the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include Lisa H. ...
Breaking Biology Technology:
(Date:1/7/2019)... ... January 07, 2019 , ... Concerto HealthAI, a ... precision health in oncology and other key therapeutic areas, and its Chief Executive ... entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, at ...
(Date:1/5/2019)... ... January 04, 2019 , ... Join Bill Fox, Chief ... Life Sciences from MarkLogic – for a live webinar on Wednesday, ... challenges of using real world data for pharmacovigilance, and the implications of current ...
(Date:1/4/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 03, 2019 ... ... to rapidly adopt 3D cell culture models into their drug discovery research workflows ... these models improve the in vivo relevancy of in vitro studies, they create ...
Breaking Biology News(10 mins):